Systems and methods related to drug delivery are provided. In one arrangement, a fluid is administered to a subject in drinkable form, which can partially or fully solidify in the stomach or another area of the gastrointestinal tract to form a drug release article or composition.
Systems, methods and composition for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising novel TnpB polypeptides and a reprogrammable targeting nucleic acid component and methods and application of use are provided.
A method can include providing a first neural network connected to a second neural network. The first neural network can represent B+11 and the second neural network can represent electrical properties. The method can include training the first neural network and the second neural network jointly. The method can include determining, from the trained first neural network and the trained second neural network B+11, a prediction of and electrical properties at one or more predetermined locations. The method can include outputting the prediction of B+11 and EP.
Aspects of the disclosure relate to reagents, compositions, kits, and methods associated with liposome-mediated delivers7 of cargo in response to an environmental trigger. Some aspects of the present invention relate to treating a diseased cell, tissue, or organ using the reagents.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
5.
REPROGRAMMABLE TNPB POLYPEPTIDES WITH MAZE DOMAINS AND USES THEREOF
Systems, methods and composition for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising novel TnpB polypeptides and a reprogrammable targeting nucleic acid component and methods and application of use are provided.
A reactor system and method for oxidizing methane can include an environmentally friendly catalyst material that converts methane to an oxidized product at low temperatures and concentrations, for example, to reduce or eliminate methane in coal mine air, dairy barns, oil and gas fields, and direct air conversion applications.
Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen/immune receptor interactions, in a single-cell format.
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A Rogowski-style current sensor includes a twisted pair of wires or cables formed into a coil. A second coil formed from another pair of wires or cables, twisted in the opposite direction, may be placed alongside, but not necessarily immediately adjacent to, the first coil, and the signals from each twisted pair may be added or subtracted to measure the enclosed current or a diamagnetism. When the current to be measured is a plasma current in a tokamak, the current sensor may be placed behind shielding tiles on the inner wall of a vacuum vessel that contains the plasma. Another current sensor may be placed on an external wall of the vacuum vessel, and the outputs subtracted to measure a current flowing through only the vessel itself.
G01R 15/18 - Adaptations providing voltage or current isolation, e.g. for high-voltage or high-current networks using inductive devices, e.g. transformers
G01R 19/00 - Arrangements for measuring currents or voltages or for indicating presence or sign thereof
9.
CARBON ELECTRODES WITH SPATIAL GRADIENTS IN POROSITY FOR HIGH-POWER REDOX FLOW BATTERIES
SINGAPORE-MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY CENTRE (Singapore)
Inventor
Han, Jongyoon
Chew, Sing Yian
Nguyen, Tan Dai
Tan, Zu Yao, Jerome
Jeon, Hyungkook
Roxby, Daniel, Ninio
Abstract
The invention relates to methods and devices for size-based separation of undifferentiated cells from a population of cells using curvilinear microfluidic channels. The curvilinear microfluidic channels may be a spiral microfluidic channels. The differentiated cells are spinal cord progenitor cells (SCPCs), neural progenitor cells (NPCs) and/or cells differentiated therefrom. The method may comprise flowing an input population of cells through first and second sequentially connected and fluidically communicating curvilinear microfluidic channels, wherein the first channel is coupled to an inlet and the second channel is coupled to one or more outlets, wherein the first curvilinear microfluidic channel has a smaller cross-sectional area than the second curvilinear microfluidic channel.
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
Systems and methods related to determination of patient parameters such as intracranial pressure (ICP), intracranial compliance (ICC), and cerebrovascular resistance (CVR) are provided. In some instances, the parameters are determined based at least in part on measures two or more parameters related to distension of a vessel and blood flow through the vessel (e.g., arterial blood pressure and cerebral blood flow). In some instances, the parameters are determined based at least in part on measurements performed using one or more probes (e.g., a single probe) at a single patient site. The systems and method described may, in some instances, facilitate determination of these parameters non-invasively and/or at a point-of-care.
A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
13.
METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT DISCOVERY OFPEPTIDE-MHC TARGETING BINDING PROTEINS
The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR T cells capable of binding to peptides bound to specific MHC alleles.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
14.
MICROFILTRATION DEVICE, METHOD OF PREPARING THE SAME, METHOD OF SEPARATING BIOLOGICAL MATERIAL AND A KIT
Disclosed herein is a microfiltration device comprising a microfilter coated with a positively charged degradable layer and a method of preparing the microfiltration device. In particular, the positively charged degradable layer comprises a polymer substrate and a cation, and wherein the polymer substrate is alginate gel and the cation is calcium (II). Also disclosed is a method of separating a biological material from a sample using said microfiltration device and a kit comprising said microfiltration device. In particular, the biological material is a negatively charged bacteria, fungus, or virus. The microfiltration device and method of separating a biological material described herein demonstrate good compatibility with various downstream analysis techniques.
The present invention presents improved systems and methods for performing multi-photon lithography. A line-scanning temporally focused two-photon lithography (LS-TFTPL) technique is capable of patterning three-dimensional structures with high throughput. An example LS-TFTPL system may include a pulsed laser, first optical components for expanding light pulses into an elongated or line cross section, a digital micromirror device for modulating the light pulses with a linear pattern and dispersing spectral components of the modulated light pulses, and second optical components for focusing the dispersed spectral components of the modulated light pulse at a line in or on a target material. The focused spectral components may alter the target material within selected voxels along the line, where the selected voxels spatially correspond to the linear pattern.
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
Described in certain example embodiments herein are programmable nuclease¬ peptidase compositions, systems, and methods for the manipulation of nucleic acids and/or polypeptides. In some embodiments, the programmable nuclease-peptidase composition comprises a repeat-associated mysterious protein (RAMP) polypeptide; a guide molecule capable of forming a RAMP-guide molecule complex with the RAMP polypeptide and directing sequence specific binding of the complex to a target polynucleotide; and a peptidase capable of binding to the RAMP polypeptide, the guide molecule, or further complexing with the RAMP-guide molecule complex, wherein binding of the RAMP-guide molecule complex to the target polynucleotide initiates binding and/or interaction of the peptidase with a target polypeptide.
17.
NOVEL COMBINATION OF RIFAXIMIN AND CLARITHROMYCIN FOR TREATING MULTIDRUG-RESISTANT MYCOBACTERIUM ABSCESSUS
The present invention relates to a novel synergistic combination of rifaximin and clarithromycin. The invention also relates to a kit comprising such combination, and such combination for use as pharmaceuticals, for instance in the treatment of bacterial diseases, including diseases caused by pathogenic mycobacteria such as clarithromycin-resistant and clarithromycin non-resistant non-tuberculosis mycobacteria.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
What is described herein is a device for sensing a target, comprising a planar array of unique stochastic sensors, wherein each sensor is weakly cross-reactive with a unique determinant on the target; a means for capturing electrical signals from each sensor and the temporal duration of each signal; and a means for analyzing the cumulative signals from the array of stochastic sensors, and optionally further comprising a computer system for processing an algorithm for identifying the target based on the electrical signals from the sensors of the device.
19.
RECHARGEABLE BATTERIES, INCLUDING ORGANIC BATTERIES
Rapid charging and high energy density are valuable battery attributes. However, high performance batteries with both of these attributes can be difficult to achieve. Conventional high performance batteries rely on metal-based electrodes including materials that can be difficult to source. Batteries with high capacity, even during rapid charge-discharge cycling, are herein provided. According to some embodiments, a battery provided herein includes an organic electrode and an organic, non-aqueous solvent system. Constituents of the organic electrode may be additionally advantaged by the comparative ease with which they may be sourced.
What is disclosed herein is a composition comprising a mixture of a soluble polymer in a solvent and an immiscible highly-soluble molecule in the same solvent, wherein the immiscible highly-soluble molecule substitutes inorganic ions, wherein the solubility of the immiscible highly-soluble molecule is more than 50 times higher than the solubility of the soluble polymer in the solvent, and wherein the soluble polymer can be cross linked to become insoluble during a material fabrication process. Also disclosed is a method of making the composition, a microneedle comprising the composition, methods for making a silk protein nanostructure array, and silk protein nanostructure arrays.
222 in contact with the composite second electrode; where the solid-state electrolyte is disposed between the first electrode and the composite second electrode. Methods of making the battery and methods of producing electricity with the battery are also described.
22.
INTEGRATING BIOPOLYMER DESIGN WITH PHYSICAL UNCLONABLE FUNCTIONS FOR ANTICOUNTERFEITING AND PRODUCT TRACEABILITY
Compositions are provided that include a first product with a physical unclonable function (PUF) tag including silk particles conformably and directly attached to the first product, wherein the PUF tag cannot be reattached to a second product once removed from the first product.
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01D 53/46 - Removing components of defined structure
Systems and methods for electrochemical target species separation are described herein. In some embodiments, a target species can be transported, in response to an applied voltage, from a fluid in a first electrically conductive tube (e.g., a tubular electrode) that has a low concentration of the target species to a fluid in a second electrically conductive tube (e.g., a tubular electrode) that has a high concentration of the target species. The transport of the target species may involve the diffusion of the target species through porous walls of the first and second tube. In some embodiments, the target species comprises gases such as acid gases (some of which may be commonly exhausted from powerplants and/or industrial processes).
B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
Systems and methods are provided for semi-automated, portable, ultrasound guided cannulation. The systems and methods provide for image analysis to provide for identification of anatomical landmarks from image data. The image analysis provides for guidance for insertion of a cannulation system into an airway of a subject which may be accomplished by a non-expert based upon the guidance provided. The system further enables a single person to perform the cannulation rather than the typical 2 or more people. The guidance may include an indicator or a mechanical guide to guide a user for inserting the cannulation system into a subject to penetrate the airway of interest.
22 masks (110) on 2-inch substrates (100) to define selective or confined growth areas. Each growth area or trench (102) is just a few microns wide and is filled with a single-domain ML (124) before the second set of nuclei (132) is introduced. Growing the second set of nuclei (132) within the trenches yields an array of single-domain bilayers (124, 134) at the 2-inch wafer scale. Devices made with the single-domain bilayers exhibit excellent performance over the entire wafer.
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
C23C 14/22 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
C23C 16/30 - Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
Systems and methods for redox-driven gas separation are generally described. What is described herein is a method, apparatus, and system for the photoelectrochemical capture of acid gases from a fluid gas mixture, as well as the photoelectrochemical release of the captured acid gas into a concentrated stream of the acid gas. Certain embodiments are related to photoelectrochemical systems comprising a photoelectrode which, upon illumination with light, induces oxidation or reduction of redox-active species in an electrolyte solution in the system, that, when brought into contact with a fluid gas mixture including an acid gas, capture acid gases from the fluid gas mixture by raising the pH of the electrolyte solution or chemically binding to the acid gas molecule. The methods, apparatuses, and systems described herein are useful in carbon capture and pollution mitigation applications, and in direct use of solar energy to drive the capture and release of acid gases from fluid gas mixtures.
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 53/00 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols
29.
OPTICAL PARAMETRIC AMPLIFICATION PROTOCOLS FOR QUANTUM NONDEMOLITION MEASUREMENT
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
NTT RESEARCH, INC. (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Nehra, Rajveer
Yanagimoto, Ryotatsu
Hamerly, Ryan
Ng, Edwin
Marandi, Alireza
Mabuchi, Hideo
Abstract
Methods and systems are presented for using optical parametric amplifiers in various ways that enhance a native quadratic coupling strength so that a photonic component of interest can be measured or otherwise observed without demolishing the component of interest at a system output. For example such components may include a number of signal Bogoliubov excitations, a pump modular quadrature, or a signal quadrature squared.
G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
G06N 10/60 - Quantum algorithms, e.g. based on quantum optimisation, or quantum Fourier or Hadamard transforms
G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computers; Platforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing
30.
COMPOSITIONS AND METHODS FOR MITIGATING AGGREGATION OF AND RECYCLING OF NANOSCALE CATALYSTS
What is described herein are nanostructures, compositions comprising the nanostructures, and related methods. In some embodiments, the nanostructure comprises an aramid amphiphile and a functional moiety associated with the aramid amphiphile. In some cases, the functional moiety may be configured to perform catalysis. According to some embodiments, a nanostructure comprising an aramid amphiphile, comprising a cysteine charged group; and a functional moiety selected from the group consisting of a nanoparticle, an enzyme, and a metal complex; wherein the functional moiety is bound to the aramid amphiphile through the cysteine is described. Also disclosed are uses of the nanostructures as catalysts in chemical reactions.
Disclosed are methods for full morphological labeling of individual neurons from any species or cell type for subsequent cell-delineated protein analysis. These methods, which combines patch-clamp electrophysiology with epitope-preserving magnified analysis of proteome (eMAP), additionally allow for correlation of physiological properties with subcellular protein expression.
Genetic circuits that control transgene expression in response to pre-defined transcriptional cues would enable the development of smart therapeutics. The present disclosure relates to engineered programmable single-transcript RNA sensors in which adenosine deaminases acting on RNA (ADARs) autocatalytically convert trigger hybridization into a translational output. This system amplifies the signal from editing by endogenous ADAR through a positive feedback loop. Amplification is mediated by the expression of a hyperactive, minimal ADAR variant and its recruitment to the edit site via an orthogonal RNA targeting mechanism. This topology confers high dynamic range, low background, minimal off-target effects, and a small genetic footprint. The circuits and systems disclosed herein leverage an ability to detect single nucleotide polymorphisms and modulate translation in response to endogenous transcript levels in mammalian cells.
The present disclosure provides a protein which is composed of a sequence including one amino acid sequence among the following (a)-(c) and forms a complex with a guide RNA: (a) an amino acid sequence which includes an amino acid sequence composed of at least amino acid numbers 198-614 in the amino acid sequence represented by SEQ ID NO: 1, and includes a substitution of one or both of E172 and E297; (b) an amino acid sequence in which at least one amino acid is deleted, inserted, substituted, or added in portions other than amino acid numbers 172 and 297 in the amino acid sequence represented by (a); and (c) an amino acid sequence which shares an identity of at least 80% with portions other than amino acid numbers 172 and 297 in the amino acid sequence represented by (a). This protein is a Cas13bt3 variant having improved efficiency and specificity.
This disclosure provides systems, methods, and compositions for site specific genetic engineering comprising the use of CRISPR effectors and trans-splicing. The disclosure also relates to methods of using the systems and compositions for treating diseases as well as diagnostics.
The present disclosure provides polymers comprising nl2 instances of a moiety of Formula (I): or a salt thereof. The present disclosure also provides methods of preparing the polymers and methods of degrading the polymers. Contacting the polymers with a fluoride nucleophile (e.g., tetrabutylammonium fluoride) or acid (e.g. octanoic acid) may degrade the polymers by cleaving the O-Si bonds. The polymers may be useful as degradable polymers, adhesives, coatings, elastomers, sealants, flexible foams, or structural materials.
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C08G 18/70 - Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
C08G 18/71 - Monoisocyanates or monoisothiocyanates
C07F 7/08 - Compounds having one or more C—Si linkages
36.
END-TO-END MACHINE LEARNING-DRIVEN DESIGN OF PROTEINS
Described herein are techniques for designing proteins for binding to a target. In some embodiments, the techniques include: obtaining an amino acid sequence for a candidate protein that binds to the target with a candidate binding affinity; determining, for proteins in a set of proteins, probabilities that binding affinities between the proteins and the target are greater than the candidate binding affinity, and identifying a subset of the set of proteins based on the determined probabilities. Determining a first probability that a first binding affinity between a first protein and the target is greater than the candidate binding affinity may include: processing a first amino acid sequence of the first protein using a trained machine learning model to obtain a first output indicative of the first binding affinity; and determining the first probability using the first output indicative of the first binding affinity between the first protein and the target.
Methods for consolidating scrap metal into a sheet metal for subsequent use are disclosed. The methods can include forming a container, such as a pipe or tube, out of a sheet metal such that one end of the container is closed and the other is open. The scrap metal can then be placed into the container, even without pre-treating the scrap metal. Oxygen can be removed from an internal, receiving cavity of the formed container, such as by introducing a gas such as argon or nitrogen, into the container, and, if desired, the open end of the container can be sealed. The combination of the container made from the sheet metal and the scrap metal can be roll bonded to form a consolidated sheet metal that includes both the original sheet metal and the scrap metal. Systems for performing these methods, as well as the consolidated metal, are also described.
Disclosed are methods of RNA-triggered protein cleavage by the CRISPR Cas7-11-Csx29 complex. A guide RNA specifically hybridizes to a RNA target, and Csx29 cleaves Csx30 when Cas7-11 :Csx29 complex binds to the target RNA.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
The present disclosure describes articles, systems, and methods for sensing and/or identifying objecting using color-dynamic, mechano-responsive photonic materials.
Compositions and methods of glycosylated virus-like particles (VLPs) displaying user-defined antigens and optionally encapsidating TLR ligands for targeting dendritic cell lectins have been developed. The VLPs employ ligands for a DC lectin e.g., DC-SIGN to activate dendritic cells (DC) and drive proliferation of antigen-specific CD8 and CD4-T cells specific for a user-defined antigen, such as a tumor antigens. In some forms, the compositions include aryl-mannose ligands to effectively generate DC-mediated TH-1 T cell responses to the user-defined antigen.
An electrodialysis system controller is configured to be coupled to a power supply, and powered devices that include a pump, and an electrodialysis unit. The controller receives inputs including an input indicative of a flow rate through the electrodialysis unit, an input indicative of a concentration level of fluid in the electrodialysis unit, and an input indicative of a power differential (e.g., indicating a degree to which a power usage by the powered devices differs from available power of the power source), and provides outputs for controlling the powered devices, including an output for causing a variable current level to be applied in the electrodialysis unit, and an output for causing a variable fluid flow rate through the electrodialysis unit. The controller is configured to match the power usage to the available power, for example, to keep the power differential as small as possible, while maximizing the theoretical desalination rate of the electrodialysis system.
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
C02F 1/00 - Treatment of water, waste water, or sewage
H02M 3/158 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load
G05F 1/67 - Regulating electric power to the maximum power available from a generator, e.g. from solar cell
H02M 3/07 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using resistors or capacitors, e.g. potential divider using capacitors charged and discharged alternately by semiconductor devices with control electrode
G05B 11/32 - Automatic controllers electric with outputs to more than one correcting element
G05B 11/10 - Automatic controllers electric in which the output signal represents a continuous function of the deviation from the desired value, i.e. continuous controllers the signal transmitted being dc
42.
METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC CELLS
Described herein are hematopoietic cell-specific targeting moieties and compositions including the hematopoietic cell specific targeting motifs. Also described herein are uses of the hematopoietic cell-specific targeting motifs and compositions including the hematopoietic cell specific targeting moieties. In some embodiments, the hematopoietic cell-specific targeting moieties and compositions including the hematopoietic cell specific targeting moieties can be used to direct delivery of a cargo to a hematopoietic cell.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A flow control system that produces smooth flow for on-chip pneumatic micropumps has been developed. By establishing a flow control system that can achieve smooth flow, fluidic conditions of microphysiological systems can be controlled to accurately mimic biological conditions. Biological experiments can require flow profiles anywhere on the spectrum of smooth flow to highly pulsatile flow. A smooth flow profile can be modified with pumping delays to make the flow profile as pulsatile as desired.
ININ) seen at the input of the MOTMN; (2) a distribution of rf power to the multiple outputs of the MOTMN; and (3) phases (including relative phases) of rf signals propagating through the MOTMN.
Electric machines and related methods are generally described. In some embodiments, an electric machine may be integrated with a thermal management system for high specific power output performance. The construction and operational parameters of the systems may be 5 precisely designed to achieve high specific power outputs between 10 kW/kg and 25 kW/kg. The thermal management system may include a heat exchanger integrated directly into the electric machine for enhanced thermal transport out of the system. A fluid (e.g., air) may flow through various flow paths throughout the system to increase cooling of the system.
Electric machines and related methods are generally described. In some embodiments, an electric machine may be integrated with a thermal management system for high specific power output performance. The construction and operational parameters of the systems may be 5 precisely designed to achieve high specific power outputs between 10 kW/kg and 25 kW/kg. The thermal management system may include a heat exchanger integrated directly into the electric machine for enhanced thermal transport out of the system. A fluid (e.g., air) may flow through various flow paths throughout the system to increase cooling of the system.
A tool for management of irrigation schedules is provided. The tool can include a controller that can communicate with an irrigation system to build and implement automatic irrigation schedules using sensed data about the environment, historical data, and manually input data. These schedules can be optimized for capital cost, lifetime cost, farm revenue, water use, and energy efficiency of the irrigation system. The schedule can be adjusted based on sensed data and/or manual inputs to ensure optimal use of resources. In some embodiments, the controller can communicate the schedule to a user via electronic communication to implement irrigation. In such embodiments, the user can interface with the controller to confirm directions to implement irrigation and receive additional directions.
A01G 25/00 - Watering gardens, fields, sports grounds or the like
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
G05B 13/00 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion
G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators
Described herein are systems and methods for the catalytic deoxygenation of lignin to generate low-oxygen aromatics that may be useful as a sustainable aviation or marine fuel. The provided systems and methods may be performed continuously without the need for a solvent, increasing both efficiency and cost effectiveness.
B01J 23/16 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
According to some embodiments, a method of decoding data includes: receiving data compressed by a universal encoder and a data model based on a sum-product network (SPN) representing statistical structure inherent to source data, the source data corresponding to an uncompressed version of the data; and decompressing the data using the data model.
H03M 13/11 - Error detection or forward error correction by redundancy in data representation, i.e. code words containing more digits than the source words using block codes, i.e. a predetermined number of check bits joined to a predetermined number of information bits using multiple parity bits
50.
SYSTEMS, DEVICES, AND METHODS FOR RHEOLOGICAL MEASUREMENT OF GRANULAR MEDIA
The present disclosure is directed to system, devices, and methods for making rheological measurements of granular media, such as powders, in both the quasistatic and transitional regimes. A rheometer includes a material engagement device attached to a rotating device and placed in a cup that contains powder to be analyzed. The material engagement device can include a plurality of inclined blades connected to a central spindle. Each blade can include a top surface having an initial angle of elevation with respect to a plane perpendicular to the axis of rotation of the spindle to form a helicoid. The helix angle can be varied from 10° to 35° and blade count from two to six to assess rheological measurement data.
B01F 27/1144 - Helically shaped stirrers, i.e. stirrers comprising a helically shaped band or helically shaped band sections with a plurality of blades following a helical path on a shaft or a blade support
G01N 11/14 - Investigating flow properties of materials, e.g. viscosity or plasticity; Analysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
B01F 27/051 - Stirrers characterised by their elements, materials or mechanical properties
B01F 27/072 - Stirrers characterised by their mounting on the shaft characterised by the disposition of the stirrers with respect to the rotating axis
B01F 27/1125 - Stirrers characterised by the configuration of the stirrers with arms, paddles, vanes or blades with vanes or blades extending parallel or oblique to the stirrer axis
Systems and related methods for assisting a user are disclosed. An end effector may be moved to assist the user in the world space. A visual representation of an avatar may be generated and superimposed on a corresponding location of the end effector in a virtual space. Poses, configurations, and movements of the avatar in the virtual space may be synchronized with the corresponding poses, configurations, and movement of the end effector in the world space. The virtual space may be displayed to a user, optionally using a wearable display configured to be worn by the user.
A structural supercapacitor, and methods of manufacturing, composed of a conductive composite is described herein. An embodiment of the composite has a controllable transport porosity, that enables transport of electrical charge, via electrolyte solution, to a distributed conductive network within the composite. The distributed conductive network has a controllable storage porosity that enables the storage of electrical charge. The conductive composite can be used in a variety of different fields of use, including, for example, a structural super-capacitor as an energy solution for autonomous housing and other buildings, a heated cement for pavement de-icing or house basement insulation against capillary rise, a protection of concrete against freeze-thaw (FT) or alkali silica reaction (ASR) or other crystallization degradation processes, and as a conductive cable, wire, or concrete trace.
The exponential growth in deep learning models is challenging existing computing hardware. Optical neural networks (ONNs) accelerate machine learning tasks with potentially ultrahigh bandwidth and nearly no loss in data movement. Scaling up ONNs involves improving scalability, energy efficiency, compute density, and inline nonlinearity. However, realizing all these criteria remains an unsolved challenge. Here, we demonstrate a three-dimensional spatial time-multiplexed ONN architecture based on dense arrays of microscale vertical cavity surface emitting lasers (VCSELs). The VCSELs, coherently injection-locked to a leader laser, operate at gigahertz data rates with a 7T-phase-shift voltage on the 10-millivolt level. Optical nonlinearity is incorporated into the ONN with no added energy cost using coherent detection of optical interference between VCSELs.
H01S 5/04 - Processes or apparatus for excitation, e.g. pumping
H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]
Provided herein, in various embodiments, are methods and compositions comprising a Signal Regulatory Protein Alpha (SIRPα) therapeutic. In certain embodiments, the disclosure provides for methods and compositions for modulating SIRPα expression. In certain embodiments, the methods and compositions are useful in the treatment of a SIRPα-mediated disease or condition.
The present disclosure provides photocleavable linkers capable of embedding proteins, of biological samples, within swellable materials, methods for extracting at least one protein from a biological sample, and methods for protein identification in biological samples.
C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
Described in several example embodiments herein are engineered programmable pattern recognition compositions and uses thereof. In certain example embodiments, the engineered protein contains an NTPase of a Signal Transduction ATPases with Numerous- associated Domains (STAND) superfamily (STAND NTPase), comprising a pathogen- associated molecular pattern (PAMP) recognition activity, wherein the STAND NTPase and the PAMP recognition activity are derived from the same or different prokaryotes.
An exemplary imaging system is provided. The imaging system includes a light source configured to illuminate a plurality of spatially separated regions of a material structure producing a first illumination. A lens produces an image of the spatially separated regions. A lens array magnifies the spatially separated regions of the image. The lens array produces a mosaic image comprised of magnified subimages of each region spatially separated region. A camera sensor to record the image.
This patent application relates generally to mixture deconvolution systems and methods for identifying DNA profiles. Various embodiments of the present invention concern the deconvolution of unknown DNA profiles in a two-person DNA mixture into two DNA profiles. Deconvolution methods isolate distinct DNA profiles from a DNA mixture without the need to match against DNA reference profiles. Various embodiments include a mixture deconvolution pipeline that involves a series of mathematical steps and machine learning algorithms to achieve the desired performance and decision-support outputs. Various embodiments enable distant familial matching to existing investigative genetic genealogy (IGG; also known as forensic genetic genealogy (FGG)) databases. This capability enables the generation of investigative leads from unresolved casework samples (i.e., DNA mixtures) by identifying possible genealogical relationships to one or more person(s) of interest. Such aspects may be performed in association with one or more systems used for genetic identification.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
Engineered or non-naturally occurring systems and compositions comprising novel Cas5- HNH and Cas8-HNH polypeptides are detailed herein. Also provided are methods and applications for the novel Cas5-HNH and Cas8-HNH polypeptides for reprogrammable targeting nucleic acid and polynucleotide components.
C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
A peristaltic pump comprises a tube (410) in contact with one or more rollers (420), wherein the tube (410) comprises a flexible material, and wherein walls of the tube in contact with the rollers comprise notches (412). The rollers (420) each consist of a compliant outer layer (422) comprising a flexible material and a rigid inner layer (424), wherein the peristaltic pump is configured for producing a vacuum. Also disclosed is a method of making the tube (410) and rollers (420) of the peristaltic pump.
An electrochemical direct air capture of carbon dioxide using a reversible redox-active material in an aqueous solution enabled by the inclusion of a hydrotropic agent. The electrochemical system demonstrates a high electron utility in continuous flow cell.
B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
This steel compositions for use in additive manufacturing are disclosed. In some embodiments, a metal alloy includes a majority iron in addition to carbon, molybdenum, vanadium, and tungsten. Overall, there may be a ratio of a combined atomic percentage of molybdenum, vanadium, and tungsten relative to carbon that is between or equal to 2:1 and 5:1. Other components such as grain refiners and/or oxidation resistant materials may also be included in such an alloy.
What is disclosed herein are quadrupole mass filters (QMF) and related methods. The QMFs may have a relatively high surface roughness and/or be additively manufactured, wherein the QMF may be configured for ion filtering in a mass spectrometer. The methods may comprise: a. applying transverse sections to produce a dielectric part; b. masking one or more surfaces of the dielectric part to produce a partially masked dielectric part; c. positioning a metal on the partially masked dielectric part with a metal conductor to produce one or more electrically conductive surfaces on the printed part; and d. removing the mask from the printed part to produce a finished QMF; wherein the QMF is configured for ion filtering in a mass spectrometer.
Radio Frequency Identification (RFID) tags having functionalized carbon nanotubes (CNTs) engineered to change in resistance when exposed to a variety of analytes to provide an inexpensive framework for distributed sensing. For example, a printing process can be developed for liquid inks comprising CNTs, and RFID sensors can be fabricated with functionalized CNTs as the active elements. The tags can work independent of distance and can sense changes in resistance of a sensing element. The tags can include an antenna with an inductive loop and two sets of dipole arms having functionalized carbon nanotubes, and a RFID chip that separates the two sets of dipole arms. The dipole arms can capture an analyte on a plurality of sensors and generate a plurality of resonant peaks therefrom. The peaks can be analyzed by comparing the damping therebetween, or by shifting the resonant frequency of the tag to determine presence of the analyte.
G06K 7/00 - Methods or arrangements for sensing record carriers
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
G06K 19/07 - Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards with integrated circuit chips
Provided herein are inorganic nucleic acid supramolecular structures and methods for making them. In certain aspects, the construct includes a structured nucleic acid polymer micelle, which micelle includes a structured nucleic acid template; one or more functional moieties attached to the template; and polymers that interact with nucleic acid present in the template to form the structured nucleic acid polymer micelle; and an inorganic shell surrounding the structured nucleic acid template, in which the one or more functional moieties extend outside the structured nucleic acid polymer micelle and the inorganic shell to maintain functionality.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Described in certain example embodiments herein are engineered delivery vesicle generations systems capable of producing engineered delivery vesicles containing two or more different retroelement polypeptides. Also described herein are methods of making and using the engineered delivery vesicles, such as to deliver one or more cargoes.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
69.
THIN, FLEXIBLE ELECTRONIC DEVICES AND ASSOCIATED SYSTEMS AND METHODS
H03H 9/17 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator
H03H 9/25 - Constructional features of resonators using surface acoustic waves
H03H 3/02 - Apparatus or processes specially adapted for the manufacture of impedance networks, resonating circuits, resonators for the manufacture of electromechanical resonators or networks for the manufacture of piezoelectric or electrostrictive resonators or networks
H03H 3/08 - Apparatus or processes specially adapted for the manufacture of impedance networks, resonating circuits, resonators for the manufacture of electromechanical resonators or networks for the manufacture of resonators or networks using surface acoustic waves
H03H 9/145 - Driving means, e.g. electrodes, coils for networks using surface acoustic waves
The present disclosure provides compositions, reagents, and methods for producing capped, circular RNA molecules, circularized RNA molecules, and in particular, circularized mRNA molecules encoding a polypeptide such as a therapeutic protein.
Disclosed embodiments may include systems and methods of a permanent magnet (PM) hybrid core inductor and fabrication methods thereof. The permanent magnet hybrid core may include a first set of members comprising a soft magnetic material, the first set of members forming a first gap between two end faces of the first set of members, and a second set of members comprising a permanent magnetic material and located adjacent to the first set of members, wherein the second set of members provides at least a partially parallel path to the first set of members for flow of magnetic flux lines. Some embodiments may include an inductor comprising the permanent magnet hybrid core, or a power conversion circuit including a switched capacitor circuit and a switching regulator, the switching regulator including an inductance, the inductance comprising an electrical conductor wound around a permanent magnet hybrid core.
Gardnerella vaginalisGardnerella vaginalis in a subject involve administering to the subject an effective amount of a composition. The composition can include one or more of galactose, D-fucose, or mucin 5B. The composition can include one or more of galactose, N-acetyl D-galactosamine, N-acetyl D-glucosamine, D-fucose, or mucin 5B bonded to a surface, such as a polymer surface.
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
A61P 15/02 - Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
Methods of fabricating a compliant prosthetic foot are provided. A method includes optimizing a set of determinants defining a shape of a compliant prosthetic foot. The shape comprises a keel curve, a heel curve, and a forefoot curve, each of the heel curve and the forefoot curve at least partially defined as an offset curve with respect to a representation of an arched ground-facing surface of the compliant prosthetic foot. The optimizing includes minimizing a lower leg trajectory error associated with the set of determinants relative to a target kinematic data set. The method further includes fabricating the compliant prosthetic foot in conformance with the optimized set of determinants.
DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN, EIN LEIBNIZ-INSTITUT (Germany)
CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (Germany)
Inventor
Birnbaum, Michael
Huisman, Brooke
Romagnani, Chiara
Rückert, Timo
Abstract
Peptides capable of binding to HLA-E and affecting immune cell activity are provided. Such peptides can selectively activate NKG2C+ immune cells such as natural killer (NK) cells and/or can inhibit NKG2A+ cells to decrease or suppress immune cell responses. Methods of use of the peptides are also disclosed, for instance, for treating or inhibiting the development or progression of a multitude of illnesses and conditions, including autoimmune disease, infectious disease such as viral or bacterial infection, and proliferative disorders such as cancer.
Compositions and methods for reducing or eliminating biofilm formation are disclosed. The compositions include an O-glycan substituted silk fibroin with a predetermined degree and distribution of O-glycan substitution. The O-glycan substituted silk fibroin is not cytotoxic to the population of biofilm-forming microbes, but it reduces or prevents biofilm formation, nonetheless.
A stellarator structure includes HTS cables. The cable includes a former with at least one channel and a tape stack in at least one channel of the former. The at least one channel and the tape stack are twisted along a longitudinal direction.
A solid-state electrochemical cell includes a solid electrolyte where at least a portion of the electrolyte is in a compressive stress state. The compressive stress state includes at least one stress component that is orthogonal to the preferred direction of dendrite growth, which may correspond to the direction of an electric field. If the magnitude of the stress component is sufficiently large (e.g., greater than 50 MPa), then the growth of a dendrite passing through that portion of the electrolyte may be suppressed or deflected towards the direction of the applied stress component. In this manner, a dendrite may be deflected away from a cathode, thus prolonging the life of the cell. The compressive stress state may be generated by applying an external mechanical load to the cell and/or generating a residual stress in the cell during manufacture or assembly.
Extremely Large Area Integrated Circuits (ELAIC) may become an attractive tiling method for 2D integration to meet the demands of higher functionality in ever smaller packages, especially when coupled with the use of heterogeneous chips. This new tiling solution is suitable for combining multiple memory, ASICs, CPU, GPU, etc., into a single package. This approach also favors system integration with high density power delivery by appropriate build-up materials, design and thermal management. ELAIC technology with bare multi-die integration offers a number of advantages relative to the equivalent integration methods.
H01L 25/065 - Assemblies consisting of a plurality of individual semiconductor or other solid state devices all the devices being of a type provided for in the same subgroup of groups , or in a single subclass of , , e.g. assemblies of rectifier diodes the devices not having separate containers the devices being of a type provided for in group
H01L 23/48 - Arrangements for conducting electric current to or from the solid state body in operation, e.g. leads or terminal arrangements
H01L 23/532 - Arrangements for conducting electric current within the device in operation from one component to another including external interconnections consisting of a multilayer structure of conductive and insulating layers inseparably formed on the semiconductor body characterised by the materials
H01L 27/06 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including integrated passive circuit elements with at least one potential-jump barrier or surface barrier the substrate being a semiconductor body including a plurality of individual components in a non-repetitive configuration
79.
RIBOZYME-ASSISTED CIRCULAR RNAS AND COMPOSITIONS AND METHODS OF USE THERE OF
The disclosure features compositions, systems, and methods for preparation and use of efficient RNA nuclear export of ribozyme-assisted circular RNA molecules (racRNAs). In embodiments, the methods involve characterizing a cell or tissue using racRNAs.
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Chimeric, engineered DNA-targeting IscB systems, methods and compositions including novel chimeric IscB polypeptides and reprogrammable targeting nucleic acid components and methods and application of use are provided.
This disclosure provides systems, methods, and compositions for RNA-guided RNA-targeting CRISPR effectors for the treatment of diseases, and for use as diagnostics. In addition, nucleotide deaminase functionalized CRISPR systems for RNA editing RNA knockdown, viral resistance, splicing modulation, RNA tracking, translation modulation, and epi-transcriptomic modifications are disclosed. In particular mutants of the Cas7-ll from Desulfonema ishimotonii (DiCas7-ll) were used in the application.
The subject matter disclosed herein is generally directed to methods of detecting treatment refractory cancer and treatment thereof In example embodiments, specific biomarkers expressed specifically in pancreatic cancer subtypes are disclosed. The biomarkers can be used for therapeutic targeting of pancreatic cancers. The biomarkers can be used for noninvasive diagnostic methods.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present disclosure relates generally to technologies comprising engineered immune cells that express chimeric antigen receptors (CARs) that specifically bind to a membrane-inserting amphiphilic ligand. Also disclosed herein are methods and compositions for treating a tumor.
Provided are engineered viral vectors, compositions comprising viral vectors, and methods of producing and using engineered viral vectors. The engineered viral vectors provided herein include capsid proteins derived from densovirus (DNV). Such DNV capsid proteins can assemble in mammalian cells and encapsulate adeno-associated virus (AAV) and/or DNV genomic DNA. The engineered viral vectors may be used as delivery vectors in target gene therapies.
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
e.g.e.g., pants, shorts) that includes a wearable harness embedded or otherwise associated with the garment in a manner that allows the garment to be worn without the harness being outwardly noticeable. The garment can be worn in conjunction with being connected to a walker or other mobility aid vehicle, as well as in everyday use. The harness associated with the garment provides support for the user while a majority of the harness is invisible from outside the garment. A connector can be utilized in conjunction with the same to help manage the connection between the harness and the mobility aid vehicle. The connector can include the ability to mitigate or stop a fall in response to parameters detected by sensors associated with the garment or system.
Chondrogenic potential of mesenchymal stem cells (MSCs) can be determined using magnetic resonance relaxometry by measuring T2 relaxation value of the MSCs.
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
Membranes and related systems and methods for separation of components in liquids are generally described. The membrane may include particles in a polymer matrix (e.g., a polyamide layer). The particles may include metal-organic framework particles comprising functional groups (e.g., from post-synthetic modification) that can, in some instances, improve the rejection and/or selectivity of the membrane. For example, the metal-organic framework may comprise functional groups bound to hydrophobic groups (e.g., alkyl chains) that assist with suspension stability in nonpolar solvents during membrane fabrication. As another example, the metal-organic framework may comprise functional groups bound to crosslinking agents that facilitate in situ crosslinking of the particles with the polymer matrix, thereby reducing voids in the membrane and/or leaching. In some instances, the membrane is a thin-film nanocomposite membrane (e.g., for separating components like charged species and/or neutral species) formed via, for example, interfacial polymerization in the presence of the particles.
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
88.
COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E
This disclosure relates to synthetic peptides, peptidomimetics, and complexes of synthetic peptides and peptidomimetics with HLA-E, methods of making such peptides, peptidomimetics, and complexes, and methods of using such peptides, peptidomimetics and complexes for blocking, inhibiting, or preventing the interaction of HLA-E with CD94/NKG2A or activation of CD94/NKG2A by HLA-E. The synthetic peptides, peptidomimetics, and complexes of synthetic peptides and peptidomimetics with HLA-E can further comprise warheads to introduce covalent linkages between the synthetic peptides and peptidomimetics with HLA-E.
Described herein are engineered paraneoplastic Ma protein (PNMA) capable of forming a capsid. In some embodiments, the engineered PNMA proteins comprise one or more modifications that enhance binding or loading of a cargo into the capsid, one or more modifications that modify cell-specificity of the capsid, one or more modifications that enhance intracellular delivery of the capsid, or a combination thereof. Also described herein are delivery systems comprising capsids comprising an engineered PNMA protein and a cargo.
This invention provides compositions, reagents, methods, and kits for producing derivatized RNA molecules, particular mRNA molecules encoding a polypeptide and in particular a therapeutic protein, derivatized by linkage to a peptide, aptamer, synthetic DNA or RNA oligonucleotide or molecular probe, capable of targeting the derivatized RNA molecules to a particular subcellular location in a target cell.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
91.
METHOD AND APPARATUS FOR DETERMINING ABNORMAL CARDIAC CONDITIONS NON-INVASIVELY
Disclosed herein are fusion protein, comprising (a) at least one XI domain comprising a. half-life extension compound, including but not limited, to a half-life extension polypeptide; (b) at least one X2 domain comprising an anionic block; (c) at least one X3 domain comprising a linker susceptible to cleavage at a site of disease, including but not limited to a microbial infection site or tumor site; and (d) at least one X4 domain comprising a therapeutic peptide; wherein the at least one XI, X2, X3, and X4 domains are covalently linked, and each X4 domain is linked to an X3 domain without an intervening XI or X2 domain; compositions containing such fusion proteins, and methods for their use.
A mixed ionic and electronic conductors (MIEC) material for a battery includes a combination of niobium (Nb), tungsten (W), titanium (Ti), and/or oxygen (O) forming a super- MIEC material with an increased alkali ion metal diffusivity. In one example, the MIEC material is a Nb-W-Ti-0 material with an anion-to-cation ratio ranging from about 2.33 to about 2.8 where the anion is O and the cation is Nb, W, and Ti. The MIEC material may be a coarse-grained material that includes particles consisting essentially of Nb, W, Ti, and/or O and having a dimension of at least 0.1 µm. The MIEC material may have an open pore structure with pores having a pore diameter from about 2.5 Å to about 2.8 Å. The MIEC material may also include carbon (C) that coats each particle. The MIEC material may be incorporated into an anode or a cathode of a lithium-ion battery.
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
A glucose sensor is configured to be wrapped around a surface of an injection needle or cannula. The glucose sensor measures a glucose concentration of a patient when the injection needle or cannula is inserted into the patient. The glucose sensor includes a flexible substrate, at least two electrodes disposed on a surface of the flexible substrate, a glucose- responsive hydrogel at least partially disposed on a first electrode of the at least two electrodes, and a membrane permeable to glucose. The membrane is disposed on the glucose-responsive hydrogel. The total thickness of the glucose sensor is less than 10 pm.
Viscoelastic hydrogel microparticles are used for repair of tissue defects and injuries or filling and occlusion of anatomical structures. These are administered as a microparticle suspension using a catheter, syringe, steerable catheter tip, or comparable technology into the site, where they can be further stabilized by crosslinking or sealing, or through incorporation of a support or encapsulating structure. Materials and methods for solidifying, stabilizing and sealing these materials can be used that are also biocompatible and easily deployed with catheters in the body. The micron sized interstitial spacing provides a scaffold for ingrowth and migration of cells into the gel matrices.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
Described in certain example embodiments herein are programmable nuclease¬ peptidase compositions, systems, and methods for the manipulation of nucleic acids and/or polypeptides. In some embodiments, the programmable nuclease-peptidase composition comprises a repeat-associated mysterious protein (RAMP) polypeptide; a guide molecule capable of forming a RAMP-guide molecule complex with the RAMP polypeptide and directing sequence specific binding of the complex to a target polynucleotide; and a peptidase capable of binding to the RAMP polypeptide, the guide molecule, or further complexing with the RAMP-guide molecule complex, wherein binding of the RAMP-guide molecule complex to the target polynucleotide initiates binding and/or interaction of the peptidase with a target polypeptide.
Bulk nanocomposite materials comprising a solid support material and a plurality of elongated nanostructures distributed within the solid support material, and related systems and methods, are generally described. The elongated nanostructures occupy a volume fraction of at least 5 vol.%;less than or equal to 20 vol.% of the domain is occupied by voids having a volume of at least 10<7>micrometer<3>; the domain comprises a first dimension having a length of at least 1 centimeter; and the domain comprises a second dimension that is perpendicular to the first dimension, the second dimension having a length of at least 1 centimeter.
C04B 35/16 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on silicates other than clay
C04B 35/453 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zinc, tin or bismuth oxides or solid solutions thereof with other oxides, e.g. zincates, stannates or bismuthates
C04B 35/515 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides
C04B 35/524 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbon, e.g. graphite obtained from polymer precursors, e.g. glass-like carbon material
C04B 35/56 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides
C04B 35/571 - Fine ceramics obtained from polymer precursors
C04B 35/626 - Preparing or treating the powders individually or as batches
C04B 35/80 - Fibres, filaments, whiskers, platelets, or the like
Aspects of the present disclosure are directed to a device configured to be inserted into a well plate. The device may include a main body having a top side and a bottom side, and a plurality of posts extending downwardly from the bottom side of the main body, where the plurality of posts is sized to be inserted into a well plate. The device may further include a plurality of post passageways extending through the plurality of posts. The plurality of posts each have a terminus end opposite the main body, where the terminus ends of the plurality of posts further include a plurality of tapered tips. The present disclosure is also directed to methods of processing a plurality of samples in a well plate using the above-described device.
A spiral inertial microfluidics device has been designed for use as a microfluidic sorting device. The device includes a spiral microchannel in which particles or cells of different sizes go through regions having different magnitudes of inertial and/or drag forces and equilibrate at different lateral positions in the microchannel so that those particles or cells of different sizes are separated. Using different focusing characteristics of larger versus smaller particles/cells in the spiral microchannel, adventitious agents (AAs) such as bacteria, virus, mycoplasma, etc. can be selectively removed from cells such as those producing therapeutic enzymes or monoclonal antibodies or those comprising the product itself.
Compositions for local delivery of a drug to an intracranial region, such as brain tissue or a brain tumor. Methods for locally delivering drug or therapy to an intracranial region. Compositions may include a hydrogel in which a chemotherapy drug or immunotherapy drug is dispersed. Kits that include compositions or solutions that may be combined to form compositions.
patents
